In summary, the study showed that the use of MDM2 antagonists such as APG-115 can enhance the antitumor efficacy of PD-1, importantly, this effect is independent of the p53 status of the tumor itself (Fig. 1). The gene discussed is TP53; the disease is neoplasm.